IgA neuropathy (IgAN) is rare and often a sign of a serious underlying condition. Early recognition and comprehensive evaluation are critical for proper diagnosis and treatment.
IgA neuropathy refers to peripheral neuropathy associated with immunoglobulin A (IgA) monoclonal gammopathy, a condition where an abnormal IgA protein is produced by plasma cells. It is relatively rare compared to neuropathies linked with IgM or IgG monoclonal gammopathies.
In a cohort of 585 patients with IgA monoclonal gammopathy, 13.5% had neuropathy, but only 1.7% of the entire cohort had neuropathy directly related to IgA. The most common causes of IgA-related neuropathy are AL amyloidosis (8 cases) and POEMS syndrome (2 cases), both of which are serious, treatable conditions.
Patients with IgA-related neuropathy often present with neuropathic pain, autonomic dysfunction (e.g., orthostatic hypotension, gastrointestinal issues), fatigue, and unexplained weight loss. A lambda light chain is typically associated with these
The link between IgA monoclonal gammopathy and neuropathy is less established than with IgM. There is no consistent autoantibody (e.g., anti-MAG) known to drive IgA neuropathy, and IgA-related neuropathy is often misdiagnosed or overlooked. Nerve biopsy and tissue evaluation (e.g., salivary gland or endomyocardial biopsy) may be required to confirm amyloidosis or POEMS.
While some cases progress slowly, others show progressive disability. Treatment is targeted at the underlying condition—e.g., disease-modifying therapies for AL amyloidosis or POEMS. Immunomodulatory treatments like prednisone or intravenous immunoglobulin (IVIG) may be tried in selected cases, especially if neuropathy is severe. Kidney damage necessitating frequent dialysis may be required.
The term “IgA neuropathy” is not a standalone disease. It is a paraproteinemic neuropathy that arises in the context of IgA monoclonal gammopathy, often signaling a more serious underlying disorder such as amyloidosis or POEMS syndrome. The pathophysiology is poorly understood.
The microbiome involvement – dysbiosis
IgAN has increasingly been linked to gut microbiome dysbiosis, with emerging evidence pointing to a critical role of the gut-kidney axis in its pathogenesis. Patients with IgAN exhibit significant alterations in gut microbiota composition, including reduced microbial diversity, decreased levels of beneficial bacteria such as Bifidobacterium, Blautia, Faecalibacterium, and Lachnoclostridium, and an increase in potentially pathogenic genera like Escherichia-Shigella, Bacteroides, and Clostridium. These changes are associated with elevated levels of gut-derived metabolites (e.g., LPS, indoxyl sulfate) and increased intestinal permeability, promoting systemic inflammation and immune activation.
Gut microbiota dysbiosis contributes to IgAN through multiple mechanisms: it may drive the overproduction of galactose-deficient IgA1 (Gd-IgA1), the hallmark autoantigen in IgAN, by stimulating B-cell activation via TLR4/MyD88/NF-κB signaling. Studies using fecal microbiota transplantation (FMT) in mice have shown that transferring microbiota from IgAN patients can induce IgA deposition in the glomeruli, supporting a causal role. Furthermore, specific microbial taxa—such as Coprococcus, Dorea, Blautia, and Lactococcus—are inversely correlated with urine Gd-IgA1 levels, suggesting their potential as biomarkers or therapeutic targets.
Therapeutic strategies targeting the gut microbiome are under investigation, including probiotics (e.g., Lactobacillus casei), prebiotics, fecal microbiota transplantation (FMT), and dietary interventions, which have shown promise in reducing proteinuria and hematuria in some patients. These findings highlight the gut microbiome as a key modifiable factor in IgAN, offering new avenues for diagnosis, prognosis, and treatment.
















